Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAN2 Therapeutics Inc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$0.23 | -$0.23 | -$0.23 |
| Q2 2026 | 1 | -$0.23 | -$0.23 | -$0.23 |
| Q3 2026 | 1 | -$0.22 | -$0.22 | -$0.22 |
| Q4 2026 | 1 | -$0.22 | -$0.22 | -$0.22 |
AN2 Therapeutics Inc Earnings Date And Information
AN2 Therapeutics Inc last posted its earnings results on Monday, May 11th, 2026. The company reported $-0.29 earnings per share for the quarter, missing analysts' consensus estimates of $-0.23 by $0.06. The company had revenue of 0 for the quarter and had revenue of 0 for the year. AN2 Therapeutics Inc has generated $-1 earnings per share over the last year ($-1.16 diluted earnings per share) and currently has a price-to-earnings ratio of -4.25. AN2 Therapeutics Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
AN2 Therapeutics Inc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/11/2026 | Q1 2026 | -$0.23 | -$0.29 | -0.06 | $0 | $0 |
| 03/17/2026 | Q4 2025 | -$0.24 | -$0.29 | -0.05 | $0 | $0 |
| 11/12/2025 | Q3 2025 | -$0.23 | -$0.31 | -0.08 | $0 | $0 |
| 08/12/2025 | Q2 2025 | -$0.31 | -$0.21 | 0.1 | N/A | $0 |
| 05/13/2025 | Q1 2025 | -$0.26 | -$0.35 | -0.09 | N/A | $0 |
| 03/25/2025 | Q4 2024 | -$0.25 | -$0.25 | 0 | N/A | $0 |
| 11/13/2024 | Q3 2024 | -$0.37 | -$0.43 | -0.06 | N/A | $0 |
| 08/13/2024 | Q2 2024 | -$0.63 | -$0.48 | 0.15 | N/A | $0 |
| 05/14/2024 | Q1 2024 | -$0.61 | -$0.56 | 0.05 | N/A | $0 |
| 03/29/2024 | Q4 2023 | N/A | -$0.57 | N/A | N/A | $0 |
| 11/09/2023 | Q3 2023 | -$0.63 | -$0.65 | -0.02 | N/A | $0 |
| 08/10/2023 | Q2 2023 | -$0.85 | -$0.81 | 0.04 | N/A | $0 |
| 05/11/2023 | Q1 2023 | -$0.68 | -$0.75 | -0.07 | N/A | $0 |
| 03/29/2023 | Q4 2022 | -$0.63 | -$0.66 | -0.03 | N/A | $0 |
| 11/09/2022 | Q3 2022 | -$0.59 | -$0.56 | 0.03 | N/A | $0 |
| 08/11/2022 | Q2 2022 | -$0.45 | -$0.52 | -0.07 | N/A | $0 |
| 05/10/2022 | Q1 2022 | -$0.52 | -$0.40 | 0.12 | N/A | $0 |
| 12/31/2021 | Q4 2021 | N/A | -$0.42 | N/A | N/A | $0 |
| 09/29/2021 | Q3 2021 | N/A | -$0.63 | N/A | N/A | $0 |
| 06/29/2021 | Q2 2021 | N/A | -$0.49 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
AN2 Therapeutics Inc Earnings: FAQ's
The conference call for AN2 Therapeutics Inc's latest earnings report can be listened to online.
The conference call transcript for AN2 Therapeutics Inc's latest earnings report can be read online.
AN2 Therapeutics Inc (:ANTX) has a recorded net income of $-35,174,000.AN2 Therapeutics Inc has generated $-1.16 earnings per share over the last four quarters.
AN2 Therapeutics Inc (:ANTX) has a price-to-earnings ratio of -4.25 and price/earnings-to-growth ratio is -0.14.